These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15356915)

  • 21. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Scientific value of the EUROPA Study: mechanisms of beneficial effect of perindopril in atherosclerosis].
    Karpov IuA
    Kardiologiia; 2005; 45(2):86-9. PubMed ID: 15798719
    [No Abstract]   [Full Text] [Related]  

  • 23. ACE inhibitors: the impact of the EUROPA study on CAD.
    Cardiovasc J S Afr; 2003; 14(4):211-2. PubMed ID: 14619870
    [No Abstract]   [Full Text] [Related]  

  • 24. New pathophysiological insights explain life-saving benefits of perindopril in coronary artery disease patients.
    Cardiovasc J S Afr; 2004; 15(5):248-9. PubMed ID: 15483736
    [No Abstract]   [Full Text] [Related]  

  • 25. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
    Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
    Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ["Using chance, despite high NNT"].
    Zeiher A
    MMW Fortschr Med; 2003 Sep; 145(38):12. PubMed ID: 14603674
    [No Abstract]   [Full Text] [Related]  

  • 27. Arterial remodelling: an independent pathophysiological component of atherosclerotic disease progression and regression. Insights from serial pharmacological intervention trials.
    Schoenhagen P; Sipahi I
    Eur Heart J; 2007 Oct; 28(19):2299-300. PubMed ID: 17766283
    [No Abstract]   [Full Text] [Related]  

  • 28. PERTINENT (a substudy of the EUROPA trial): a persistent legacy.
    Kaski JC; Consuegra-Sanchez L
    Cardiovasc Res; 2012 Nov; 96(2):202-3; discussion 204-7. PubMed ID: 22815531
    [No Abstract]   [Full Text] [Related]  

  • 29. Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients.
    Redekop WK; Orlewska E; Maciejewski P; Rutten FF; Niessen LW
    Pharmacoeconomics; 2008; 26(10):861-77. PubMed ID: 18793033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE.
    Verma S; Leiter LA; Lonn EM; Strauss MH
    Eur Heart J; 2005 Jul; 26(14):1347-9. PubMed ID: 15872030
    [No Abstract]   [Full Text] [Related]  

  • 31. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Coronary heart disease patient with no ischemic symptoms. Does he still profit from an ACE inhibitor?].
    MMW Fortschr Med; 2003 Sep; 145(38):12. PubMed ID: 14603673
    [No Abstract]   [Full Text] [Related]  

  • 33. EUROPA shows role for ACE inhibition in low-risk CHD.
    Owen OG
    Int J Clin Pract; 2003 Oct; 57(8):726-8. PubMed ID: 14627186
    [No Abstract]   [Full Text] [Related]  

  • 34. Perindopril: the reasonable choice in patients with coronary artery disease.
    Cockcroft JR
    Int J Clin Pract; 2005 May; 59(5):600-4. PubMed ID: 15857358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
    Simoons ML; Vos J; de Feyter PJ; Bots ML; Remme WJ; Grobbee DE; Kluft C; de Maat MP; Fox KM; Deckers JW
    Eur Heart J; 1998 Sep; 19 Suppl J():J56-60. PubMed ID: 9796842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
    Fox KM; Henderson JR; Bertrand ME; Ferrari R; Remme WJ; Simoons ML
    Eur Heart J; 1998 Sep; 19 Suppl J():J52-5. PubMed ID: 9796841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Suppression of angiotensin-converting enzyme and myocardial ischemia].
    Eliseev OM
    Ter Arkh; 1999; 71(3):73-6. PubMed ID: 10234773
    [No Abstract]   [Full Text] [Related]  

  • 38. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
    J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood pressure and stroke; the PROGRESS trial.
    He FJ; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):153-5. PubMed ID: 11881116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.